Samphire Neuroscience Raises $5M Seed Round for Novel Neurotech Wearable Targeting Menstrual Pain

Samphire Neuroscience Raises $5M Seed Round for Novel Neurotech Wearable Targeting Menstrual Pain Samphire Neuroscience has raised $5 million in seed funding to expand its Nettle brain device for menstrual symptoms, following strong market reception since its European launch earlier this year. The round was led by Nordic venture capital firm Inventure VC, with participation from US-based Fortify Ventures. Read More from the Global Wellness News…

Middle East Travel Spending to Hit 350 Billion USD by 2030 Amid Surge in Business, Luxury and Sports Tourism

Middle East Travel Spending to Hit 350 Billion USD by 2030 Amid Surge in Business, Luxury and Sports Tourism – Travel And Tour World Middle East travel spend will grow 50% by 2030 to $350B, driven by luxury, business, and sports tourism, according to ATM and Tourism Economics report. Read More from the Global Wellness News ™

Femtech market booms, to hit $75B this year | Europe & Middle East’s travel markets surge; US falls | AI health coaches evolve, grab funding

Headlines in the Global Wellness Economy Global Wellness News™ | June 5th, 2025 ‘Femtech’ takes on the women’s health-care marketplace A fast-growing industry offers high-tech solutions for feminine health problems. Its many female founders say they’re tackling the age-old equity gap in health care. Europe’s tourism on the rise while US takes a breather Europe is set to see an 11% increase in international tourist…

McKinsey’s new global wellness survey: Gen Z & millennials drive the market | London plans $2.7B wellness ‘village’ | Wellness hotels/resorts outperform the market

Headlines in the Global Wellness Economy Global Wellness News™ | June 3rd, 2025 The $2 trillion global wellness market gets a millennial and Gen Z glow-up Our latest Future of Wellness survey finds that distinct consumer segments are catalyzing demand for goods and services in six wellness subcategories. Wellness hotels outperformed the market in 2024 finds RLA Global insight | spabusiness.com news Hotels incorporating significant…

Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin

Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of weight-loss drugs called amylins is drawing the drug industry’s attention and dollars. Read the article on Barrons > Read More from the Global Wellness News ™